The Role of Life Sciences M&A

Learn more about the role that life sciences M&A plays in:

Driving New and Novel Drug Launches

Bringing Innovative Treatments to Patients

Fueling Local Economic Growth

Driving New and Novel Drug Launches

Recent data shows that there is a robust positive association between life sciences mergers and acquisitions (M&A) and the likelihood of new and novel therapies coming to market — and reaching patients.

Life sciences M&A can increase the likelihood of new drugs making it to patients — with drugs in development that undergo M&A nearly twice as likely to launch than non-acquired ones.

M&A also brings new drugs to patients by allowing large companies to provide the resources, expertise and infrastructure that small companies need to bring treatments to patients — with drugs in development which undergo M&A between a large and small firm about three times more likely to launch.

Bringing Innovative Treatments to Patients

Life sciences M&A has driven the launch of new treatments, including:

Momelotinib is the only first-line medicine for the treatment of anemia in patients with myelofibrosis, a rare and serious blood cancer, treating the leading cause of treatment discontinuation. Learn More

Luxturna is the first gene therapy ever approved to treat an inherited genetic disease, serving patients as a one-time treatment for a rare form of vision loss. Learn More

Nipocalimab is a first-in-class therapy providing new hope for patients with generalized myasthenia gravis, a rare and debilitating autoimmune disease. Learn More

Learn more about innovations advanced by life sciences M&A.

See All News

Fueling Local Economic Growth

Across the country, life sciences M&A helps to support jobs, fuel economic growth, and bring new treatments to patients. Hear from some of PULSE’s partners on the impact of M&A in their communities:
“Much of Michigan’s success in the life sciences is owed not just to the state-of-the-art institutions in our state, but also to the robust collaboration and partnerships between them.”
– Stephen Rapundalo, President & CEO, MichBio
“M&A allows Colorado’s life sciences companies to raise capital, cultivate scientific discoveries, and deliver groundbreaking innovations to patients.”
– Colorado Bioscience Association
“M&A enables universities and small companies to specialize in early discovery while connecting them with the infrastructure, capital, and expertise necessary to bring them to patients — creating real pathways for new medicines and new ideas to succeed in the market.”
– Kristin Jones, CEO, Indiana Life Sciences Association
“M&A and other strategic collaborations have been key to fueling decades of growth in Utah’s life sciences industry.”
– Kelvyn Cullimore, CEO, BioUtah

Learn more about the impact of M&A on states and local communities across the country.

See All News